pharma-drugs-pixa

An end to Obamacare and a less aggressive approach to drug pricing expected

Pharmaceutical stocks surged in Europe on Wednesday as Republican Donald Trump’s U.S. presidential election win led investors to conclude the threat of tough action on drug pricing had receded.

tech-council-md-industry-awards-2017-logo

Nominations are open for the 2017 Industry Awards Celebration. This will be our 29th year of recognizing the companies and individuals in the region who make a difference.

The Tech Council ignites the power of three by bringing together a trio of industries that are accelerating our local ecosystem—technology, life sciences, and health IT. It’s our mission to make this region a top three innovation economy, so we’re redefining what’s possible and helping to shape the future through ideation, collaboration, and innovation.

cms-logo

Concerns over the role of the Center for Medicare & Medicaid Innovation could lead to legislation intended to hinder the agency and slow its attempts to further the goal of paying providers for value rather than volume.

While no specific legislative language has surfaced, multiple sources confirmed that Republicans upset with what they say is overreach by the CMS Innovation Center, also known as CMMI, are considering a legislative response. A few Republicans have previously said they would support repealing the agency entirely or zeroing out its budget. More modest efforts could include banning mandatory participation in payment models.

kauffman-foundation-logo

Get in the habit of producing good financial reports every single month. But you need more than just standard financial reports. You need a Management Dashboard that monitors critical metrics that may not pop out of your accounting reports. These monthly reports are a learning opportunity: What did we think would happen? What actually happened? Why was there a difference? Are we on track to hit our key milestones?

immunomic-thera-logo

Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery Incubator Award.

After experiencing partnering success and a $315 million deal with Japan-based Astellas Pharma Inc. for their LAMP-Vax platform technology in allergy, Immunomic Therapeutics, in concert with BioHealth Innovation, is giving back to the region's growing scientific community with the Cancer Discovery Incubator Award. The incubator will enable and accelerate beginning ventures aimed at offering measurable change in oncological healt

BioIT-10-year-logo

Join BioBuzz as we partner with BioIT Solutions to celebrate their 10th Anniversary at Growlers in Gaithersburg on November 16, 2016. BioIT Solutions offers a range of services from enterprise systems built on their 1Platform4 Suite for advanced computational, workflow, and data management systems to IT strategy, architecture and management consulting. The 1Platform Suite consists of a software foundation on which various highly configurable modules are assembled and tailored to each client’s specifications and needs.  

The company was founded by IT experts who have worked in the biotechnology sector for over 20 years in a variety of information-technology capacities, including senior positions as CIO, and directors of Bioinformatics, Quality Systems and Clinical Systems at companies including Human Genome Sciences (now part of GlaxoSmithKline). The breadth of our experience makes us an ideal partner for early-stage companies, as well as those with legacy systems in need of modernization.

Bhi event nov 29 machine learning

Tuesday, November 29th | 10:00am – 12:00 pm Rockville Innovation Center, 155 Gibbs Street, Rockville, MD 20850

Hosted by BioHealth Innovation 

You’ve probably heard about the Cloud, Big Data and Machine Learning, but where does the hype end and the true value of these technologies begin? Can, or should, your business leverage these technologies? Mark Weston and Matt Puglisi from Netrias LLC (www.netrias.com) will describe the current state of the art for Cloud computing, Big Data and Machine Learning to help you better leverage these technologies for your business.

Mark Weston, Chief Software Architect, is a software engineer with extensive experience in applying distributed database technologies to problems at scale. Matt Puglisi, Chief Executive Officer is a seasoned leader with successful experience as a technology company executive, a leader of research and development efforts, government service, and military service

Please RSVP by November 22nd to Joyce Debrowski (This email address is being protected from spambots. You need JavaScript enabled to view it. | (301) 279-2222). The event is open to the first 30 registrants only.

Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.  

ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA - 03 November 2016 - Actelion Ltd (SIX: ATLN) and ReveraGen BioPharma, Inc., a privately held company engaged in the discovery and development of proprietary therapeutic products for neuromuscular and inflammatory diseases, announced today that they have entered into an agreement. By this agreement, Actelion has obtained an exclusive option to in-license ReveraGen's lead compound vamorolone for the treatment of Duchenne Muscular Dystrophy at two different stages in its development.

Montgomery Community Media in partnership with the Maryland/DC District Export Council, the US Commercial Service, the Maryland Department of Commerce, and the Small Business Administration present a three-hour program on the challenges and opportunities facing companies going global.
The program will feature 3 panels covering key aspects of international trade, including trade finance and local resources that facilitate trade. Speakers include government executives as well as CEOs who have successfully taken their companies international.

The program will be filmed in front of a studio audience of business leaders and will be streamed live to http://www.MCMLive.org.

Follow this link to learn more about the previous forum and to watch the panels online: http://www.mymcmedia.org/forum-on-international-trade/

Register

vigilant-bioservices-110716-logo

Come to the "Before Party" of the Biopark's monthly Science in the City Happy Hour! Join us for a tour then you are welcome to join us at SitC Happy Hour. Alternatively, if you are visiting us from outside of Baltimore, come during low traffic hours in the middle of the day and have lunch on us. 

This Open House is designed for biotech professionals that are considering backup storage where a power outage or equipment failure could prove devastating to your initiatives. We are a boutique biorepository that work with some of the biggest names in Biotech to protect their biomaterials from equipment failure hazards.  

Actelion-logo

Eric Hoffman, PhD, writes a lot of grants, proposals and papers. A lot. As Professor and Associate Dean of Research at Binghamton University following stints at George Washington University, Harvard Medical School, and University of Pittsburgh, Dr Hoffman is used to writing a lot.

He also writes grants and proposals for his other job as CEO of Reveragen BioPharma – a small biotech company that has slowly developed a drug to treat boys with Duchenne muscular dystrophy.

international-trade-forum-logo

Fri, December 9, 2016 - 8:30 AM – 1:00 PM EST

Montgomery Community Media in partnership with the Maryland/DC District Export Council, the US Commercial Service, the Maryland Department of Commerce, and the Small Business Administration present a three-hour program on the challenges and opportunities facing companies going global.    The program will feature 3 panels covering key aspects of international trade, including trade finance and local resources that facilitate trade. Speakers include government executives as well as CEOs who have successfully taken their companies international.

roche-logo

The most interesting aspect of Foundation Medicine (NASDAQ:FMI) is that, last year, cancer giant Roche (OTCQX:RHHBY) paid $50 per share to buy a 56% stake in the company. Bill Gates and Google (NASDAQ:GOOG) (NASDAQ:GOOGL) Ventures are also owners in this genomic testing company. However, right now, the stock is trading at $22.50, about half that Roche number.

Were all these smart people wrong? Did the M&A decision makers at Roche and the analysts working for Bill Gates and Google Ventures not do their homework? Or are we missing something here?

big-data-pixa

Will big data cure cancer?

While there's a lot of breathless talk about the potential of big data to do just that, Greg Simon, the Executive Director of the White House's Cancer Moonshot Taskforce, is a skeptic--at least for now.

protenus-logo

The cofounders of healthcare cybersecurity startup Protenus are providing insight to a think tank that focuses on protecting critical infrastructure from attacks.

Robert Lord and Nick Culbertson, who launched the company through Dreamit Health Baltimore after meeting in medical school at Johns Hopkins, were named fellows with the D.C.-based Institute for Critical Infrastructure Technology.

ourcrowd-logo

Israeli equity crowdfunding platform OurCrowd has launched a new fund specifically focused on the digital health field, called OurCrowd Qure. They will work with Johns Hopkins University to provide validation of value, market access,  and on-going feedback on the startups.

"I think that crowdfunding for digital health makes a huge amount of sense," John Medved, CEO of OurCrowd, told MobiHealthNews. "We’re not just raising money in a different way. We’re helping to build the company in a different way. A crowdfunding platform is uniquely positioned to help digital health leaders."

	
CSSi-LifeSciences-logo

CSSi LifeSciences™, a trusted partner from discovery to commercialization for drugs and medical devices, is excited to announce the establishment and launch of its fully integrated Medical Device CRO. CSSi LifeSciences™ Medical Device CRO aims to positively impact the timeline of regulatory clearance and increase profitability for medical device companies, in order to successfully launch its innovative research discoveries and product concepts into the market.

inova-health-system-logo

Back in February, Inova Health System announced it would create a $100 million venture fund. It offered few details at the time.

But as Inova officials celebrated another milestone Wednesday with an new University of Virginia partnership on multiple medical, research and business fronts, CEO Knox Singleton finally offered some details on Inova's investment plans.

big-idea-connectpreneur-logo

Wednesday, December 14, 7 - 11 amFalls Church Marriott Fairview Park

Super Early Bird expires November 3rd for our CONNECTpreneur Winter Forum, headlined by Revolution Chairman & CEO, STEVE CASE, former AOL Time Warner Chair and New York Times bestselling author of The Third Wave.

The Big Idea CONNECTpreneur FORUM has been called "The Best Networking Event in DC." DCInno calls CONNECTpreneur a "NETWORKING JACKPOT" of the DC Region's TOP Entrepreneurs, Business Leaders, CXOs, Angels, and VCs.

sbir-sttr-seed-fund-logo

NIH is committed to improving the participation of all people in our small business research SBIR & STTR programs. One of the goals of the SBIR and STTR programs is to encourage participation in innovation and entrepreneurship by socially and economically disadvantaged small businesses (SDB) and women-owned small businesses (WOSB), groups who historically have been underrepresented in both the SBIR/STTR applicant and awardee pools, and have slightly lower success rates than applicants across the board.

tsunami-wave-pixa

Last week at the Cleveland Clinic’s annual Medical Innovations Summit, Daniel Kraft, chair of medicine and neuroscience at Singularity University, and an oncologist, painted a dazzling picture of a healthcare future where digital tools empower everyone and can solve several of healthcare’s bigger problems.

But he also posed a question whose answer will be borne out over the next few years: The tech and data tsunami is coming, but do we have the right platforms in place to catch the wave?

tedco-logo

TEDCO is happy to announce its new Seed Investment Fund. After careful consideration of feedback received from our recent market stakeholder survey, we've decided to transform our Technology Commercialization Fund (TCF), Cyber Security Investment Fund (CIF) and Life Science Invest,ment Fund (LSIF) into a single Seed Investment Fund.

The new program will make it easier than ever for startup technology companies to seek Seed Funding from TEDCO.

research-paper-pixa

There are a lot of scientific papers out there. One estimate puts the count at 1.8 million articles published each year, in about 28,000 journals. Who actually reads those papers? According to one 2007 study, not many people: half of academic papers are read only by their authors and journal editors, the study's authors write. 

But not all academics accept that they have an audience of three. There's a heated dispute around academic readership and citation—enough that there have been studies about reading studies going back for more than two decades.

vigilant-bioservices-logo

Vigilant Bioservices Open House In the UMB Biopark 801 W. Baltimore St., Suite 303, Baltimore, Md. 21201 (street parking & garage on same block west of Biopark)

Wednesday, November 16th

(Tours start on the half hour) 11am – 1pm 3pm – 5pm

Join us for the monthly Science in the City Happy Hour With the tenants of the Biopark 5:00pm-6:30pm

RSVP: This email address is being protected from spambots. You need JavaScript enabled to view it.

chan-zuckerberg-initiative-logo

Stephen Quake’s laboratory at Stanford University looks like biology’s version of Thomas Edison’s famous New Jersey workshop. Roll-down curtains cast shadows across odd devices buzzing and clicking in the aisles. You half expect to find Quake, author of 135 patents and rarely seen wearing anything other than a faded polo shirt, sleeping on one of the benches, just as the Wizard of Menlo Park was known to.

roche-logo

The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC).

immunomic-thera-logo

Immunomic Therapeutics is committed to providing a workplace that bolsters scientific ideas. The Cancer Discovery Incubator will enable and accelerate beginning ventures with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.